Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Developing and Optimizing Layer-by-Layer Nanoparticle Delivery of Nucleic Acid Therapy for Treating High-Grade Serous Ovarian Cancer
FY 2022-23
Summary
Advanced high-grade serous ovarian cancer (HGSOC) is the leading cause of gynecological cancer death in the developed world, with 5-year survival rates of only 25-30% due to late-stage diagnosis and the limitations of chemotherapies; this survival rate has remained unimproved since the 1980s. The existing standard of care consists of tumor removal surgery followed by chemotherapy, which has systemic toxicity affecting both tumors and healthy organs. Patients often develop resistance to chemotherapies, leading to shortened disease-free intervals, increased risk of metastasis, and worsened prognosis.
Given that many types of ovarian cancer (OC) are caused by genetic mutations, small interfering ribonucleic acid therapies (siRNAs) have emerged as promising solutions for OC by targeting the underlying mutations with high specificity and high efficiency. Using siRNAs to target multiple tumor proliferation or chemotherapy resistance pathways thus presents an exciting opportunity to reduce tumor viability without the toxicity of systemic chemotherapy combinations. However, bare siRNA is unstable and causes immune reactions, thus requiring a well-engineered delivery system.
We propose the development of layer-by-layer nanoparticles (LbL NPs) for siRNA delivery to treat OC, in which a charged NP core is layered with alternating charged polymer layers via electrostatic attraction. By incorporating the charged polymers, LbL NPs better avoid liver clearance than existing NPs and selectively target tumors without affecting healthy cells. This is particularly suitable for delivering combination therapies for HGSOC, such as an siRNA-small molecule drug combination or multiple siRNAs.
Ultimately, the development of an optimized drug delivery platform for nucleic acid delivery will be broadly impactful for therapeutic delivery in treating additional cancers and genetic diseases, reducing side effects, and significantly improving patient experience and outcomes.
Department
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
474141
Name
Cai Eva
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Developing and Optimizing Layer-by-Layer Nanoparticle Delivery of Nucleic Acid Therapy for Treating High-Grade Serous Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Biomaterials; Cancer Therapy; Drug Delivery; Materials Science; Nanomedicine; Nanoparticles; Nucleic Acid Therapeutics; Ovarian Cancer; Rna Interference (Rnai) Therapy; Systems Biology
Abstract
Advanced high-grade serous ovarian cancer (HGSOC) is the leading cause of gynecological cancer death in the developed world, with 5-year survival rates of only 25-30% due to late-stage diagnosis and the limitations of chemotherapies; this survival rate has remained unimproved since the 1980s. The existing standard of care consists of tumor removal surgery followed by chemotherapy, which has systemic toxicity affecting both tumors and healthy organs. Patients often develop resistance to chemotherapies, leading to shortened disease-free intervals, increased risk of metastasis, and worsened prognosis.
Given that many types of ovarian cancer (OC) are caused by genetic mutations, small interfering ribonucleic acid therapies (siRNAs) have emerged as promising solutions for OC by targeting the underlying mutations with high specificity and high efficiency. Using siRNAs to target multiple tumor proliferation or chemotherapy resistance pathways thus presents an exciting opportunity to reduce tumor viability without the toxicity of systemic chemotherapy combinations. However, bare siRNA is unstable and causes immune reactions, thus requiring a well-engineered delivery system.
We propose the development of layer-by-layer nanoparticles (LbL NPs) for siRNA delivery to treat OC, in which a charged NP core is layered with alternating charged polymer layers via electrostatic attraction. By incorporating the charged polymers, LbL NPs better avoid liver clearance than existing NPs and selectively target tumors without affecting healthy cells. This is particularly suitable for delivering combination therapies for HGSOC, such as an siRNA-small molecule drug combination or multiple siRNAs.
Ultimately, the development of an optimized drug delivery platform for nucleic acid delivery will be broadly impactful for therapeutic delivery in treating additional cancers and genetic diseases, reducing side effects, and significantly improving patient experience and outcomes.
Competitiondate
202210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cai, Eva
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~